Acting as investment bankers , Talley & Company raised equity capital for Mobclix, Inc. Mobclix, Inc., (the “Company” or “Mobclix”), has been formed for the purpose of commercializing its breakthrough analytics technology for mobile applications by 1) monetizing its partner mobile applications through advertising revenue 2) licensing its analytics to enterprises developing mobile applications 3) aggregating and segmenting mobile application data for market research purposes 4) assisting wireless telecommunication carriers increase their average revenue per user by monetizing native applications on mobile devices 5) enhancing advertising network revenues by providing more accurate targeting.
link to Mobclix

As a director of China Aoxing Pharmacutical Co., Mr. Talley assisted the board with American Oriental Bioengineering ( AOB NYSE) investment into China Aoxing Pharama Co. (CAXG.OB)

As Chairman of Central American Equities CEAQ (CEAQ OTCBB } Mr. Talley completed a reverse merger with Ostar Pharmaceutical,Inc. a Delaware corporation. Ostar is a holding company whose only asset is shares in Hebei Aoxing Pharmaceutical GroupCo.,Ltd. Hebei Aoxing Pharmaceutical Group Co.,Ltd is one of the first nongovernmental enterprises to enter the analgesic industry in China The company's facilities are located in Xinle City. Shijiazhuang, Hebei province, about 143 miles from Beijing.

Investment support to Café Britt Coffee Corporation, with operations based in Costa Rica. Mr. Talley has been funding the company since its inception by providing both debt and equity capital. He serves as the company's Investment Banker, providing funding and advisory services Café Britt is Costa Rica's premier coffee roaster and a leading merchandiser.

Collaboration with BNP Paribas Bank (Paris, France) in the structuring of !00% capital-protected European Medium Term Notes (EMTN) for clients of BNP Paribas managed by its offices in Geneva, Switzerland, Dubai, United Arab Emirates and London, England.

At a valuation of $14 million, Mr. Talley’s company raised substantial equity for PDT, subsequently NASDAQ: MRVT. Miravant was active in photo-dynamic cancer therapy (thereby the initial name, PDT). With advisory support from Mr. Talley, the company went public in 1995, and became one of the leading NASDAQ performers by reaching a valuation of $1.2 billion.

On an advisory basis, Mr. Talley innovatively provided start-up equity capital to one Corporation in one of the first uses of R&D Limited Partnerships for such purpose, leading to its sale to Union Carbide Corporation. The funding structure implemented by Mr. Talley allowed the company to access funds otherwise unavailable from the US financial market.

In addition to previously having provided investment support to the company, Mr. Talley joined the Board and served as Chairman of the Audit Committee of Inamed Corporation (OTC: IMDC). In such roles, Mr. Talley assisted the company in reorganizing management and revising the underlying business model. Subsequent to Mr. Talley serving the Board, Inamed's stock rose from $4 per share to a subsequent price of $75 per share.

Funding of Immulok Corporation; Mr. Talley’s company raised significant equity for this company engaged in the initial use of monoclonal antibodies in office test kits for the detection of sexually-transmitted diseases .After just 19 months, the company was sold to Johnson & Johnson for a price resulting in a five-fold return for investors.